149 related articles for article (PubMed ID: 11338880)
1. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma.
Nemunaitis J; Fong T; Shabe P; Martineau D; Ando D
Cancer Invest; 2001; 19(3):239-47. PubMed ID: 11338880
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study.
Soubrane C; Rixe O; Meric JB; Khayat D; Mouawad R
Melanoma Res; 2005 Jun; 15(3):199-204. PubMed ID: 15917702
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma.
Dummer W; Becker JC; Schwaaf A; Leverkus M; Moll T; Bröcker EB
Melanoma Res; 1995 Feb; 5(1):67-8. PubMed ID: 7734958
[TBL] [Abstract][Full Text] [Related]
4. The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma.
Tas F; Oguz H; Argon A; Duranyildiz D; Camlica H; Yasasever V; Topuz E
Med Oncol; 2005; 22(3):241-6. PubMed ID: 16110135
[TBL] [Abstract][Full Text] [Related]
5. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma.
Hoejberg L; Bastholt L; Johansen JS; Christensen IJ; Gehl J; Schmidt H
Melanoma Res; 2012 Aug; 22(4):287-93. PubMed ID: 22617301
[TBL] [Abstract][Full Text] [Related]
6. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients.
Kos J; Stabuc B; Schweiger A; Krasovec M; Cimerman N; Kopitar-Jerala N; Vrhovec I
Clin Cancer Res; 1997 Oct; 3(10):1815-22. PubMed ID: 9815568
[TBL] [Abstract][Full Text] [Related]
7. Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma.
Bosserhoff AK; Dreau D; Hein R; Landthaler M; Holder WD; Buettner R
Recent Results Cancer Res; 2001; 158():158-68. PubMed ID: 11092043
[TBL] [Abstract][Full Text] [Related]
8. An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients.
Mouawad R; Soubrane C; Rixe O; Khayat D; Spano JP
Melanoma Res; 2006 Aug; 16(4):335-40. PubMed ID: 16845329
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of serum M30 and M65 levels in melanoma.
Tas F; Karabulut S; Serilmez M; Yildiz I; Sen F; Ciftci R; Duranyildiz D
Melanoma Res; 2013 Oct; 23(5):390-5. PubMed ID: 23812330
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta.
Juergensen A; Holzapfel U; Hein R; Stolz W; Buettner R; Bosserhoff A
Tumour Biol; 2001; 22(1):54-8. PubMed ID: 11054027
[TBL] [Abstract][Full Text] [Related]
11. Serological landscape of cytokines in cutaneous melanoma.
Paganelli A; Garbarino F; Toto P; Martino GD; D'Urbano M; Auriemma M; Giovanni PD; Panarese F; Staniscia T; Amerio P; Paganelli R
Cancer Biomark; 2019; 26(3):333-342. PubMed ID: 31561328
[TBL] [Abstract][Full Text] [Related]
12. High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma.
Wang H; Wang L; Chi PD; Wang WD; Chen XQ; Geng QR; Xia ZJ; Lu Y
Br J Cancer; 2016 Feb; 114(4):463-8. PubMed ID: 26882069
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma.
Guney N; Soydinc HO; Basaran M; Bavbek S; Derin D; Camlica H; Yasasever V; Topuz E
Asian Pac J Cancer Prev; 2009; 10(4):669-74. PubMed ID: 19827892
[TBL] [Abstract][Full Text] [Related]
14. IL-8 and cathepsin B as melanoma serum biomarkers.
Zhang H; Fu T; McGettigan S; Kumar S; Liu S; Speicher D; Schuchter L; Xu X
Int J Mol Sci; 2011; 12(3):1505-18. PubMed ID: 21673904
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic role of serum interleukin-18 in gastric cancer patients.
Thong-Ngam D; Tangkijvanich P; Lerknimitr R; Mahachai V; Theamboonlers A; Poovorawan Y
World J Gastroenterol; 2006 Jul; 12(28):4473-7. PubMed ID: 16874857
[TBL] [Abstract][Full Text] [Related]
16. Serum-soluble IL-2 receptor and IL-6 levels in patients with melanoma.
Boyano MD; García-Vázquez MD; Gardeazabal J; García de Galdeano A; Smith-Zubiaga I; Cañavate ML; Raton JA; Bilbao I; Díaz-Pérez JL
Oncology; 1997; 54(5):400-6. PubMed ID: 9260602
[TBL] [Abstract][Full Text] [Related]
17. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.
Ugurel S; Rappl G; Tilgen W; Reinhold U
J Clin Oncol; 2001 Jan; 19(2):577-83. PubMed ID: 11208853
[TBL] [Abstract][Full Text] [Related]
18. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma.
Franzke A; Probst-Kepper M; Buer J; Duensing S; Hoffmann R; Wittke F; Volkenandt M; Ganser A; Atzpodien J
Br J Cancer; 1998 Jul; 78(1):40-5. PubMed ID: 9662248
[TBL] [Abstract][Full Text] [Related]
19. Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma.
Wu BJ; Li WP; Qian C; Ding W; Zhou ZW; Jiang H
Tumour Biol; 2013 Apr; 34(2):643-8. PubMed ID: 23179401
[TBL] [Abstract][Full Text] [Related]
20. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients.
De Vita F; Orditura M; Galizia G; Romano C; Roscigno A; Lieto E; Catalano G
Chest; 2000 Feb; 117(2):365-73. PubMed ID: 10669676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
